Nasus Pharma (NSRX) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nasus Pharma (NSRX) has outperformed Rein Therapeutics (RNTX) over the past year, losing 68.4% versus a loss of 77.2%. Rein Therapeutics is the larger company by market cap ($29.1 million vs $26.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NSRX | RNTX |
|---|---|---|
| Share price | $2.29 | $0.3369 |
| Market cap | $26.82M | $29.06M |
| 1-day change | -10.20% | -8.38% |
| YTD return | -74.97% | -70.96% |
| 1-year return | -68.41% | -77.24% |
| 5-year return | — | -97.47% |
| EPS (TTM) | $-1.20 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | $0 |
| Net income (latest FY) | $-5.86M | $-49.87M |
| Operating margin | -0.40% | — |
| Net margin | -0.47% | — |
| 52-week high | $9.50 | $2.10 |
| 52-week low | $1.98 | $0.284 |
| Distance from 52-week high | -75.89% | -83.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +758.95% | +1680.94% |
| Average volume | 16.80K | 586.68K |
| Shares outstanding | 11.71M | 86.27M |
| Employees | 7 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NSRX vs RNTX FAQ
Which is bigger, Nasus Pharma or Rein Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $26.82M for Nasus Pharma (NSRX).
Which stock has performed better over the past year, NSRX or RNTX?
NSRX returned -68.41% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Nasus Pharma and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.